Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts

• Published in: Metabolism, clinical and experimental Vol. 127; p. 154936
• Main Authors: Marfella, Raffaele, D'Onofrio, Nunzia, Trotta, Maria Consiglia, Sardu, Celestino, Scisciola, Lucia, Amarelli, Cristiano, Balestrieri, Maria Luisa, Grimaldi, Vincenzo, Mansueto, Gelsomina, Esposito, Salvatore, D'Amico, Michele, Golino, Paolo, Signoriello, Giuseppe, De Feo, Marisa, Maiello, Ciro, Napoli, Claudio, Paolisso, Giuseppe
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2022
• Subjects: Adult; Biopsy; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - surgery; Diabetic Cardiomyopathies - drug therapy; Diabetic Cardiomyopathies - genetics; Diabetic Cardiomyopathies - physiopathology; Diabetic Cardiomyopathies - surgery; Diabetic cardiomyopathy; Female; Follow-Up Studies; Gene Expression - drug effects; Heart - drug effects; Heart - physiology; Heart Transplantation; Humans; JunD; Lipid Metabolism - drug effects; Male; Middle Aged; Myocardium - metabolism; Myocardium - pathology; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Proto-Oncogene Proteins c-jun - genetics; Proto-Oncogene Proteins c-jun - metabolism; SGLT2i; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; JunD; IRS-2; IRS-1; IVS; HIF-1α; AP-1; HTX; ISHLT; HOMA-IR; DSA; RT-PCR; Diabetic cardiomyopathy; EMB; ALCOA; SGLT2i; PPAR-γ

The pathogenesis of experimental diabetic cardiomyopathy may involve the activator protein 1 (AP-1) member, JunD. Using non-diabetic heart transplant (HTX) in recipients with diabetes, we examined the effects of the diabetic milieu (hyperglycemia and insulin resistance) on cardiac JunD expression ov...